NCT01317017

Cell Responses to IFN-gamma

Cellular Responses To Intradermal-Gamma (IFN-gamma) in Normal and Psoriatic Patients

• Status: Terminated
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Rockefeller University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

IFN-gamma is a central player in the development of psoriasis lesions, which can be involved a variety of cellular processes in the skin. Dendritic cells are important cells in driving inflammation in psoriasis through the induction of T cells that produce IL-17 in psoriasis. Injecting IFN-g into the skin can increase the numbers of T cells and also inflammatory DCs that produce cytokines involved in IL-17 production. Thus, the investigators hypothesize that the dendritic cells present in the skin after IFN-g injection polarize IL-17-producing T cells.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Actimmune	* All subjects will receive one intradermal injections of 0.25ml of IFN-g (Actimmune TM 100 micrograms/0.5ml), in normal appearing skin of both normal volunteers and psoriasis patients. * Blood will be taken at baseline and day 1. A skin biopsy (6mm punch) will be taken at the injection site 24 hours later. * Patients will return at one to two weeks for suture removal. * Clinical assessments done at every visit. * Patients will also be evaluated at each visit for any adverse events.

Timeline

• Start date: 2010-07-01
• Primary completion: 2011-05-01
• Completion: 2011-05-01
• First posted: 2011-03-16
• Last updated: 2013-03-05

Locations

1 site across 1 country: United States